Antitrust Antitrust

Bristol Myers Squibb’s $10.8 million settlement in HIV drug antitrust case will get final approval, US judge says

By Michael Acton
  • 17 Nov 2022 22:43
  • 17 Nov 2022 22:43
Bristol Myers Squibb will get final approval of its antitrust settlement with a class of direct purchasers of HIV drugs, the California federal judge overseeing the litigation said today.
The litigation against Gilead, Bristol Myers Squibb, Janssen Pharmaceuticals, Johnson & Johnson, and Teva Pharmaceuticals alleges a conspiracy to block generic

To view the latest version of this document and thousands of others like it, sign-in to MLex or register for a free trial.

Michael Acton

Senior Correspondent

Michael is a senior correspondent for MLex in San Francisco, where he moved in 2020 after working in our Brussels bureau. Before joining MLex, he reported on EU politics as the Financial Times’ Nico Colchester Fellow in Brussels. Michael has a degree in International Relations and Politics from the University of Cambridge, and a degree in History and French from University College London and Paris IV Sorbonne.

Discover MLex

Stay on top of global regulatory developments

Latest News